Fovlussea (ranibizumab)

Where it stands

Fovlussea (ranibizumab), from Accord Healthcare S.L.U., received a positive CHMP opinion in the EU on 2026-10-15. The records list its status as "Opinion" and show no approval date, so the European Commission (EC) has not yet granted marketing authorisation as far as the records show.

The records give the indication as treatment of neovascular (wet) age-related macular degeneration (AMD) and other visual impairments in adults. The therapeutic areas tagged are wet macular degeneration, macular edema, diabetes complications and choroidal neovascularization. The records do not list the individual indications or the exact wording of the approved conditions of use.

The only forward-looking milestone is an expected EC decision on 2026-12-21. This is an estimate, calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. It is not an official date and should not be treated as a commitment.

Regulatory pathway and designations

Fovlussea carries a Biosimilar designation. A biosimilar is developed to show that it is highly similar to an already authorised biological reference medicine, with no clinically meaningful differences in quality, safety or efficacy. The records do not name the reference product used for Fovlussea, and they give no detail on the comparability package.

After a positive CHMP opinion, the EC normally adopts a legally binding decision, and that decision grants the EU-wide marketing authorisation. The CHMP opinion is a scientific recommendation and does not itself authorise marketing. The records show no other designations, such as orphan or PRIME status, and no information on the type of application.

Several ranibizumab products are already authorised in the EU: Lucentis, Byooviz, Epruvy (previously Ranibizumab Midas), Ximluci, Susvimo and Vislyfa. If Fovlussea is authorised, it would join an established group of products containing the same active substance. The records do not describe how these products differ from one another.

Safety and pharmacovigilance

The records contain no safety data for Fovlussea. They include no adverse event information, no risk management plan details, no post-authorisation commitments and no CHMP assessment conclusions on benefit-risk, so no product-specific safety conclusions can be drawn here.

As general procedure, EU authorisation of a medicine, biosimilars included, is accompanied by a risk management plan and routine pharmacovigilance obligations. These include adverse reaction reporting and periodic safety reporting. The specifics for Fovlussea would appear in the EC decision and the published product information, which are not part of these records.

What to watch

The main event is the EC decision. The estimated date is 2026-12-21, but the actual timing may differ, and the authorisation date should be confirmed from the official EC decision once it is published.

When the CHMP assessment documents and product information are published, check the exact approved indications against the broad description in the records, and look for any additional risk-minimisation measures or post-authorisation conditions. Also check the reference product used and the presentation and administration details, none of which are in the records.

The records contain no information on launch timing or market position, so these should not be inferred.